Harmony Biosciences Holdings, Inc. (HRMY) Earnings Call Transcripts
Harmony Biosciences Holdings, Inc.'s Latest Earnings Call - June 9, 2026
In the Q2 2026 earnings call, Harmony Biosciences Holdings, Inc. (HRMY:US) reported a strong trajectory towards achieving blockbuster status for its WAKIX franchise, with management projecting over $1 billion in revenue for the year. The company emphasized its commitment to protecting its intellectual property through 2030 and highlighted the potential of its new orexin-2 agonist, BP205, which is positioned as a best-in-class treatment for narcolepsy. Management maintained a positive outlook on revenue growth and pipeline development, signaling confidence in their strategic pillars for long-term value creation.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | $1B+ (positive) |
| PDUFA Date for GR Formulation | Q1 2027 (positive) |
| Operating Margin | |
| Cash on Balance Sheet | Close to $1B (positive) |
| Patient Growth | 90,000 undiagnosed patients (positive) |
| Efficacy Profile for BP205 |
Guidance from management
Management maintained a positive outlook for 2026, expecting to achieve over $1 billion in revenue and signaling confidence in their pipeline developments, particularly with BP205 and the new formulations of pitolisant.
What management said
Absolutely. I think, again, we feel really strong and confident in the strength of our IP out to 2030. And I think Peter can sort of expand on the license of tedium patent and this multilayered strategy with regards to protecting our IP.
Yes. So I think that it's the ability to dose lower and drive strong efficacy. And based on the preclinical data that we've seen over now in the clinic, with regards to sort of side effects that are on target in terms of lower percentages of those side effects and minimizing and avoiding the off-target effects. And I think that where we're seeing the class, Peter, from a commercial perspective where we see those oppo...
What analysts pressed on
Analysts expressed concerns regarding the competitive landscape for orexin therapies and the potential impact on WAKIX's market position. They are particularly focused on how the introduction of new therapies might affect patient growth and market dynamics.
Main topics on the call
- WAKIX Franchise Growth — Management confirmed that WAKIX is on track to exceed $1 billion in revenue this year, driven by strong patient growth and an established efficacy profile. "We expect that will continue" as they innovate and expand their...
- Orexin-2 Agonist Development — The company is excited about BP205, which they believe has the potential to be the most potent orexin-2 agonist in the clinic. Management stated, "We feel we have a potential best-in-class orexin," indicating strong conf...
- Intellectual Property Protection — Harmony expressed strong confidence in its IP strategy, stating, "We feel very strongly about our ability to prevail in that litigation." This underscores their commitment to protecting the WAKIX franchise through 2030.
- Life Cycle Management — The company has submitted an NDA for the gastro-resistant formulation of pitolisant, with a target PDUFA in Q1 2027. This is seen as a significant opportunity to extend the pitolisant franchise beyond 2030.
Read the full Harmony Biosciences Holdings, Inc. transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc. (HRMY) is a publicly listed company in the Pharmaceuticals industry, within the Health Care sector. It trades on NasdaqGM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 44 calls on record spanning November 12, 2020 to August 4, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 44 Harmony Biosciences Holdings, Inc. earnings call transcripts on record, spanning November 12, 2020 to August 4, 2026. Based on this history, Harmony Biosciences Holdings, Inc. reports quarterly. The most recent call on file is dated August 4, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- HRMY
- Exchange
- NasdaqGM
- Country
- US
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Calls on record
- 44
- First call
- November 12, 2020
- Most recent
- August 4, 2026
- Reporting cadence
- quarterly